A Randomized Phase II/III Study of αβ T Cell-Depleted, Related, Haploidentical Hematopoietic Stem Cell Transplant (Haplo-HSCT) Plus Rivogenlecleucel vs. Haplo-HSCT Plus Post-Transplant Cyclophosphamide (PTCy) in Patients With AML or MDS
Phase of Trial: Phase II/III
Latest Information Update: 30 Oct 2019
Price : $35 *
At a glance
- Drugs Rimiducid (Primary) ; Rivogenlecleucel (Primary) ; Cyclophosphamide
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Registrational; Therapeutic Use
- Acronyms THRIVE
- Sponsors Bellicum Pharmaceuticals
- 24 Oct 2019 Planned End Date changed from 1 Jul 2024 to 1 Jul 2038.
- 14 Mar 2019 Planned End Date changed from 1 Jun 2024 to 1 Jul 2024.
- 04 Jan 2019 Status changed from not yet recruiting to recruiting.